Table 1 Characteristics of Symptomatic Children’s COVID-19 Cases (N = 92)
From: Clinical features of pediatric post-acute COVID-19: a descriptive retrospective follow-up study
Characteristics | Value |
|---|---|
Median (interquartile range) age, years | 12 (8–15) |
Age group, No. (%): | |
1 month to < 1 year | None |
1–4 years | 10 (11%) |
5–9 years | 21 (23%) |
10–14 years | 35 (38%) |
15–18 years | 26 (28%) |
Sex at birth, No. (%): | |
Male | 56 (61%) |
Female | 36 (39%) |
Vaccination, No. (%) | |
Seasonal influenza | 12 (13%) |
Complete vaccination | 85 (92%) |
Incomplete vaccination | 12 (13%) |
Total baseline chronic medical conditions, No. (%) | 18 (20%) |
Bronchial asthma | 7 (8%) |
Attention-deficit/hyperactivity disorder | 3 (3%) |
Atopic dermatitis | 2 (2%) |
Arthritis | 1 (1%) |
Patent ductus arteriosus | 1 (1%) |
Vegetative dystonia | 1 (1%) |
Congenital hypothyroidism | 1 (1%) |
Epilepsy | 1 (1%) |
Overactive bladder | 1 (1%) |
Exposure to the source of transmission, No. (%) | |
Contact with COVID19 positive patients within the last 14 days | 66 (72%) |
Contact with group COVID-19 cases | 35 (38%) |
Contact with a person with fever / respiratory symptoms or epidemiological communities in the last 14 days | 22 (24%) |
Contact with a person who does not know the COVID-19 test results within 14 days | 18 (20%) |
Traveling in the last 14 days | 17 (18%) |
Patients from a care center | 2 (2%) |
Acute COVID-19 symptoms, No. (%) | |
Distribution of temperature, No. (%) | |
37.2–37.5 °C | 36 (39%) |
≥ 37.5–38 °C | 15 (16%) |
38.1–39.0 °C | 13 (14%) |
> 39.0 °C | 11 (12%) |
Tiredness | 42 (46%) |
Headache | 34 (37%) |
Cough | 30 (33%) |
Rhinorrhea | 29 (32%) |
Sore throat | 29 (32%) |
Loss of taste and/or smell | 27 (29%) |
Stuffy nose | 26 (28%) |
Sneezing | 22 (24%) |
Diarrhea | 17 (18%) |
Myalgia | 13 (14%) |
Shortness of breath | 10 (11%) |
Drowsiness | 7 (8%) |
Decreased appetite | 5 (5%) |
Conjunctivitis | 5 (5%) |
Wheezing | 5 (5%) |
Vomiting | 4 (4%) |
Sensory disturbances | 4 (4%) |
Sweatiness | 2 (2%) |
Epistaxis | 2 (2%) |
Periorbital edema | 1 (1%) |
Seizures | 1 (1%) |
Post–acute COVID-19 follow-up characteristics | |
Days since symptoms onset, median (interquartile range) | 55 (30–104) |
Persistent symptoms, No. (%) | |
None | 45 (49%) |
1 | 18 (19%) |
2 | 9 (10%) |
≥ 3 | 20 (22%) |